Get started

Financials · IDYA

IDEAYA Biosciences Inc. (IDYA) financials

For the twelve months ended Sep 30, 2026, IDEAYA Biosciences Inc. reported $36.53M of revenue and -$420.01M of net income.

Revenue, TTM
$36.53M
Net income, TTM
-$420.01M
Net margin
-1149.6%
Free cash flow, TTM
-$349.80M
EPS, diluted, TTM
-$4.46
Cash
$261.45M
P/S
84.77
Market cap
$3.10B
Annual revenue$218.71M
FY2019FY2025
Annual net income-$113.70M
FY2017FY2025
Annual free cash flow-$73.47M
FY2017FY2025

IDYA revenue and earnings growth

IDYA revenueQ3 2026$10.24M

Quarter YoY
-95.1%
QoQ
+15.6%
FY YoY
31x
5Y CAGR
+62.1%

IDYA revenue was $10.24M in fiscal Q3 2026 (ended Sep 30, 2026), down 95.1% from a year earlier and up 15.6% from the prior quarter. For the full fiscal 2025 it was $218.71M, up about 31-fold from fiscal 2024. Compound annual growth was +62.1% over 5 years. It rose in 3 of the last 5 fiscal years. Fiscal 2025 is the highest of the 7 fiscal years on file.

IDYA net incomeQ3 2026-$125.75M

IDYA net income was -$125.75M in fiscal Q3 2026 (ended Sep 30, 2026), compared with $119.24M a year earlier. For the full fiscal 2025 it was -$113.70M, compared with -$274.48M in fiscal 2024.

IDYA EPSQ3 2026-$1.22

IDYA diluted EPS was -$1.22 in fiscal Q3 2026 (ended Sep 30, 2026), compared with $1.33 a year earlier. For the full fiscal 2025 it was -$1.28, compared with -$3.36 in fiscal 2024.

IDYA free cash flowQ3 2026-$93.75M

IDYA free cash flow was -$93.75M in fiscal Q3 2026 (ended Sep 30, 2026), compared with $142.17M a year earlier. For the full fiscal 2025 it was -$73.47M, compared with -$251.44M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Revenue$218.71M$7.00M$23.39M$50.93M$27.94M$19.54M$0--
Research and development$314.70M$294.67M$129.51M$89.54M$58.16M$39.70M$34.32M$31.75M$12.38M
Selling, general and admin$63.32M$39.30M$28.31M$23.90M$20.05M$15.18M$9.95M$4.67M$2.05M
Operating income-$159.31M-$326.98M-$134.43M-$62.50M-$50.27M-$35.34M-$44.27M-$36.42M-$14.44M
Income tax$0$0$0$0$0$0$0$0-
Net income-$113.70M-$274.48M-$112.96M-$58.66M-$49.76M-$34.49M-$41.98M-$34.35M-$11.86M
EPS, basic-$1.28-$3.36-$1.96-$1.42-$1.41-$1.40-$3.36-$35.92-$17.06
EPS, diluted-$1.28-$3.36-$1.96-$1.42-$1.41-$1.40-$3.36-$35.92-$17.06
Diluted shares88.5M81.7M57.5M41.4M35.3M24.7M12.5M956,252695,372

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Cash and equivalents$112.83M$85.18M$157.02M$68.74M$92.15M$72.14M$34.17M$20.61M$6.03M
Short-term investments$526.56M$591.94M$368.10M$296.20M$154.72M$211.55M$64.89M$69.46M-
Receivables-$3.0K$18.0K$211.0K$1.10M$1.88M---
Current assets$666.73M$689.71M$532.63M$370.45M$251.00M$288.61M$101.65M$90.67M-
Total assets$1.11B$1.12B$649.32M$387.97M$381.35M$298.27M$113.00M$96.54M-
Current liabilities$58.81M$46.07M$27.10M$31.72M$45.16M$38.64M$6.94M$5.41M-
Total liabilities$86.39M$64.94M$28.23M$38.51M$79.83M$100.00M$12.60M$7.10M-
Shareholders' equity$1.02B$1.06B$621.09M$349.45M$301.51M$198.27M$100.40M-$48.95M-$15.74M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Operating cash flow-$71.10M-$247.58M-$115.22M-$87.17M-$55.78M$55.46M-$39.31M-$27.62M-$12.22M
Capital expenditures$2.37M$3.86M$2.37M$3.44M$2.64M$493.0K$1.35M$1.71M$1.76M
Free cash flow-$73.47M-$251.44M-$117.59M-$90.62M-$58.42M$54.97M-$40.67M-$29.33M-$13.98M
Investing cash flow$69.98M-$502.56M-$158.46M-$33.40M-$69.67M-$146.24M$2.27M-$63.18M-$8.93M
Financing cash flow$29.78M$677.55M$362.72M$97.17M$145.45M$128.75M$50.61M$105.38M$17.49M
Stock-based compensation$46.12M$34.75M$18.49M$11.63M$8.24M$3.61M$2.17M$950.0K$136.0K
Depreciation and amortization$2.70M$2.39M$2.48M$2.10M$1.73M$1.38M$1.40M$886.0K$391.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Revenue growth, YoY3024.4%-70.1%-54.1%82.3%43.0%----
Operating margin-72.8%-4671.1%-574.9%-122.7%-179.9%-180.9%---
Net margin-52.0%-3921.1%-483.0%-115.2%-178.1%-176.6%---
Free cash flow margin-33.6%-3592.0%-502.9%-177.9%-209.1%281.3%---
Return on equity-11.1%-25.9%-18.2%-16.8%-16.5%-17.4%-41.8%--
Return on assets-10.2%-24.4%-17.4%-15.1%-13.0%-11.6%-37.1%-35.6%-
Current ratio11.3414.9719.6511.685.567.4714.6516.75-

Source: XBRL data IDEAYA Biosciences Inc. files with the SEC, latest filing dated Nov 3, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

IDYA peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
IDYA$36.53M--$420.01M-1149.6%$3.10B
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

IDYA FAQ

8 questions
  • What is IDYA revenue?
    IDEAYA Biosciences Inc. (IDYA) reported $36.53M of revenue for the twelve months ended Sep 30, 2026. Revenue for fiscal 2025 was $218.71M.
  • Is IDYA profitable?
    No. IDEAYA Biosciences Inc. reported a net loss of $420.01M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does IDYA have?
    IDEAYA Biosciences Inc. reported $261.45M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is IDYA revenue growing?
    IDEAYA Biosciences Inc.'s revenue changed 31x in fiscal 2025, to $218.71M. Its compound annual growth rate was +62.1% over 5 years.
  • What is IDYA free cash flow?
    IDEAYA Biosciences Inc. generated -$349.80M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$347.36M less capital expenditures.
  • What is IDYA earnings per share?
    Diluted earnings per share were -$4.46 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did IDYA last report financial results?
    The latest statements here come from IDEAYA Biosciences Inc.'s 10-Q filed on Nov 3, 2026, covering the period ended Sep 30, 2026.
  • Where does this IDYA financial data come from?
    Quantisnow builds these statements from the structured XBRL data IDEAYA Biosciences Inc. files with the SEC. It is provided for information only and is not investment advice.